FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell Therapies
1. FibroBiologics highlights fibroblasts' advantages over stem cells in treatments.
2. The opinion piece touts fibroblasts’ scalability and effectiveness for chronic diseases.
3. Leadership anticipates a paradigm shift in chronic disease management.
4. FibroBiologics has over 270 patents in various therapeutic domains.
5. Editorial underscores the need for fibroblast-based solutions in clinical settings.
The publication strengthens FBLG's position against competitors like stem cell therapies. Historical examples show that similar breakthroughs can lead to significant price increases.
How important is it?
The article's focus on fibroblast advantages aligns directly with FBLG’s business model and future potential, suggesting significant relevance.
Why Long Term?
If the scientific claims are validated, FBLG could establish a strong market position, impacting stock prices over time, similar to other biotech advancements.
HOUSTON, Sept. 12, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the publication of an opinion editorial authored by company leadership that presents the scientific case for fibroblast cells' therapeutic advantages compared to stem cell therapies.
The article, titled "Fibroblast Cells vs. Stem Cells: A Superior Option for Chronic Disease Therapy," was authored by Pete O'Heeron, Founder and Chief Executive Officer of FibroBiologics, and Hamid Khoja, Ph.D., Chief Scientific Officer. The editorial presents a comprehensive review of published research and FibroBiologics' long-term internal scientific studies supporting the advantages that fibroblast cells offer over stem cells in treating chronic diseases, including faster proliferation rates, superior sourcing capabilities, and enhanced immune modulation properties for conditions such as multiple sclerosis, rheumatoid arthritis, and wound healing applications.
"What we're seeing is the beginning of a paradigm shift in medicine — one that will positively transform how chronic disease is treated," said Mr. O'Heeron. "Based on our extensive research using fibroblasts, the evidence is clear: fibroblasts aren't just comparable to mesenchymal stem cells, they may actually be superior. They offer scalability, effectiveness, and the potential to truly modify disease at scale. This is about building for the long term — a future where therapies don't just manage illness, they fundamentally change patient outcomes."
"Our commentary synthesizes the growing evidence base that supports the transition from stem cell therapies to fibroblast-based solutions," said Dr. Khoja. "Publications and our internal research demonstrate the potential superiority of fibroblasts in clinical utility, safety profile, scalability for clinical use, and potentially improved patient outcomes across multiple therapeutic areas."
This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning the potential advantages of fibroblast cells over stem cells and the potential of fibroblast cell therapies and of such treatments to revolutionize the treatment of chronic diseases. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of FibroBiologics' R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; and (d) the ability of FibroBiologics to successfully prosecute its patent applications. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.
